Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Atypical Ductal Breast Hyperplasia|Lobular Carcinoma in Situ (LCIS)|Atypical Lobular Hyperplasia (ALH) of Breast
Interventions: DRUG: SOM 230 / Pasireotide
Sponsor: NYU Langone Health
Collaborators: United States Department of Defense